At end point , compared to placebo , desvenlafaxine was associated with a significantly greater decrease in HDRS@ total scores ( last-observation-carried-forward analysis ; adjusted mean change from baseline -@ vs -@ , respectively ; P = @ ) and significant improvements on the CGI-I ( P < @ ) , MADRS ( P = @ ) , SDS ( P = @ ) , and VAS-PI ( P < @ ) .